MDT

88.75

+2.73%↑

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

PHR.US

8.74

-3.53%↓

MDT

88.75

+2.73%↑

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

PHR.US

8.74

-3.53%↓

MDT

88.75

+2.73%↑

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

PHR.US

8.74

-3.53%↓

MDT

88.75

+2.73%↑

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

PHR.US

8.74

-3.53%↓

MDT

88.75

+2.73%↑

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

PHR.US

8.74

-3.53%↓

Home・Akciju saraksts・Cogent Biosciences Inc

Cogent Biosciences Inc

Atvērts

36.85 3.42

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

36.22

Max

37.31

Galvenie mērījumi
By Trading Economics
Ienākumi	-22M -102M
Darbinieki	258
EBITDA	-30M -109M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+48.36% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	141M 5.7B
Iepriekšējā atvēršanas cena	33.43
Iepriekšējā slēgšanas cena	36.85

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

4.88 / 5.87 Atbalsts un pretestība

Cogent Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 7. apr. 17:26 UTC

Galvenie ziņu notikumi

EIA Raises Oil-Price Forecasts as War in Middle East Continues

2026. g. 7. apr. 23:55 UTC

Tirgus saruna

Genesis Energy Signals Higher Dividend Payout Ratios -- Market Talk

2026. g. 7. apr. 23:47 UTC

Tirgus saruna

Galvenie ziņu notikumi

Market Talk Roundup: Latest on U.S. Politics

2026. g. 7. apr. 23:47 UTC

Tirgus saruna

Galvenie ziņu notikumi

Precious Metals Rise, Boosted by Dollar Weakness, Lower Treasury Yields -- Market Talk

2026. g. 7. apr. 23:44 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Rallies as Trump Remarks Send Oil Prices Lower -- Market Talk

2026. g. 7. apr. 23:42 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 7. apr. 23:42 UTC

Tirgus saruna

Nikkei Likely to Rise After Trump Agrees to Cease-Fire With Iran -- Market Talk

2026. g. 7. apr. 23:37 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Fall After Trump Agrees to Two-Week Cease-Fire With Iran -- Market Talk

2026. g. 7. apr. 23:15 UTC

Tirgus saruna

Galvenie ziņu notikumi

Markets Will Want Fast Evidence That Ships Are Moving -- Market Talk

2026. g. 7. apr. 23:04 UTC

Galvenie ziņu notikumi

Spot Gold Rises 2.5%, Spot Silver Climbs 4.9%

2026. g. 7. apr. 23:04 UTC

Galvenie ziņu notikumi

Precious Metals Rise After Trump Agrees to Ceasefire With Iran

2026. g. 7. apr. 23:03 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 7. apr. 23:03 UTC

Tirgus saruna

Middle East Ceasefire Triggers Australian Dollar Rally -- Market Talk

2026. g. 7. apr. 23:01 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Falls 13.7% to $97.47 per Barrel

2026. g. 7. apr. 22:58 UTC

Galvenie ziņu notikumi

Front-Month Crude Oil Futures Slide After Trump Agrees to Cease-Fire With Iran

2026. g. 7. apr. 21:56 UTC

Iegādes, apvienošanās, pārņemšana

Telefónica Sells All Shares in Pegaso PCS, Celular de Telefonía

2026. g. 7. apr. 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 7. apr. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 7. apr. 19:45 UTC

Tirgus saruna

Treasury Yields Mixed as Investors Brace for Iran Deadline -- Market Talk

2026. g. 7. apr. 19:17 UTC

Galvenie ziņu notikumi

The Risks to the Gulf Region's Oil Are Immense. Are Markets Shrugging Them Off? -- Barrons.com

2026. g. 7. apr. 19:16 UTC

Tirgus saruna

Cold Shot Helps U.S. Natural Gas Futures Settle Higher -- Market Talk

2026. g. 7. apr. 19:07 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 7. apr. 19:07 UTC

Tirgus saruna

Oil Futures Mixed Ahead of Trump's Iran Deadline -- Market Talk

2026. g. 7. apr. 18:41 UTC

Iegādes, apvienošanās, pārņemšana

Eldorado Gold: Total of 149.6M Common Shrs, Representing 75.31% of Votes Attached to All Outstanding Common Shrs, Were Voted >ELD.T

2026. g. 7. apr. 18:40 UTC

Iegādes, apvienošanās, pārņemšana

Eldorado Gold Holders Voted to Approve Issuance of Common Shrs in Connection With Proposed Plan of Arrangement With Foran Mining >ELD.T

2026. g. 7. apr. 18:39 UTC

Iegādes, apvienošanās, pārņemšana

Eldorado Gold Reports Voting Results From Special Meeting of Hldrs

2026. g. 7. apr. 18:24 UTC

Galvenie ziņu notikumi

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

2026. g. 7. apr. 17:08 UTC

Tirgus saruna

Latin America Less Exposed to Crude Supply Disruptions -- Market Talk

2026. g. 7. apr. 16:21 UTC

Galvenie ziņu notikumi

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

2026. g. 7. apr. 16:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Cogent Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

48.36% augšup

Prognoze 12 mēnešiem

Vidējais 52.55 USD 48.36%

Augstākais 64 USD

Zemākais 35 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

12 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 12 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

4.88 / 5.87Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.